BridgeBio Pharma, Inc. R&D Expenses

R&D Expenses of BBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.


Highlights and Quick Summary

  • R&D Expenses for the quarter ending September 30, 2022 was $92.5 Million (a -14.66% decrease compared to previous quarter)
  • Year-over-year quarterly R&D Expenses decreased by -25.24%
  • Annual R&D Expenses for 2021 was $451 Million (a 33.82% increase from previous year)
  • Annual R&D Expenses for 2020 was $337 Million (a 60.54% increase from previous year)
  • Annual R&D Expenses for 2019 was $210 Million (a 49.88% increase from previous year)
  • Twelve month R&D Expenses ending September 30, 2022 was $432 Million (a -2.66% decrease compared to previous quarter)
  • Twelve month trailing R&D Expenses decreased by -4.48% year-over-year
Trailing R&D Expenses for the last four month:
30 Sep '22 30 Jun '22 31 Mar '22 31 Dec '21
$432 Million $444 Million $438 Million $453 Million
Visit stockrow.com/BBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of BridgeBio Pharma, Inc.

Most recent R&D Expensesof BBIO including historical data for past 10 years.

Interactive Chart of R&D Expenses of BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $92.51 $108.4 $107.65
2021 $123.75 $104.31 $101.96 $122.56 $451.02
2020 $90.17 $92.05 $86.6 $68.23 $337.05
2019 $57.49 $55.28 $52.33 $44.85 $209.95
2018 $31.15 $140.07
2017 $30.56

Business Profile of BridgeBio Pharma, Inc.

Sector: Healthcare
Industry: Biotechnology